Metzner, V.; Herzog, G.; Heckel, T.; Bischler, T.; Hasinger, J.; Otto, C.; Fassnacht, M.; Geier, A.; Seyfried, F.; Dischinger, U.
Liraglutide + PYY3-36 Combination Therapy Mimics Effects of Roux-en-Y Bypass on Early NAFLD Whilst Lacking-Behind in Metabolic Improvements. J. Clin. Med. 2022, 11, 753.
https://doi.org/10.3390/jcm11030753
AMA Style
Metzner V, Herzog G, Heckel T, Bischler T, Hasinger J, Otto C, Fassnacht M, Geier A, Seyfried F, Dischinger U.
Liraglutide + PYY3-36 Combination Therapy Mimics Effects of Roux-en-Y Bypass on Early NAFLD Whilst Lacking-Behind in Metabolic Improvements. Journal of Clinical Medicine. 2022; 11(3):753.
https://doi.org/10.3390/jcm11030753
Chicago/Turabian Style
Metzner, Valentin, Gloria Herzog, Tobias Heckel, Thorsten Bischler, Julia Hasinger, Christoph Otto, Martin Fassnacht, Andreas Geier, Florian Seyfried, and Ulrich Dischinger.
2022. "Liraglutide + PYY3-36 Combination Therapy Mimics Effects of Roux-en-Y Bypass on Early NAFLD Whilst Lacking-Behind in Metabolic Improvements" Journal of Clinical Medicine 11, no. 3: 753.
https://doi.org/10.3390/jcm11030753
APA Style
Metzner, V., Herzog, G., Heckel, T., Bischler, T., Hasinger, J., Otto, C., Fassnacht, M., Geier, A., Seyfried, F., & Dischinger, U.
(2022). Liraglutide + PYY3-36 Combination Therapy Mimics Effects of Roux-en-Y Bypass on Early NAFLD Whilst Lacking-Behind in Metabolic Improvements. Journal of Clinical Medicine, 11(3), 753.
https://doi.org/10.3390/jcm11030753